Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Lexeo Therapeutics, Inc. ( (LXEO) ).
Lexeo Therapeutics has appointed Dr. Kyle Rasbach as the new Chief Financial Officer, effective immediately. Dr. Rasbach’s extensive experience in life sciences and financial management is expected to support Lexeo’s growth as the company advances its gene therapy programs and prepares for pivotal studies.
More about Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company based in New York City, focusing on pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease.
YTD Price Performance: -52.61%
Average Trading Volume: 434,991
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $210.3M
For detailed information about LXEO stock, go to TipRanks’ Stock Analysis page.